Telo Genomics

Telo Genomics EBITDA per Share

The EBITDA per Share of Telo Genomics (TELO.V) as of Oct 22, 2026 is -0.04 CAD. In the previous year, EBITDA per Share was -0.04 CAD — a change of 0.16% (lower).

EBITDA per Share

-0.04CAD

YoY

0.16%

Last updated:

EBITDA per Share of Telo Genomics is 2025 -0.04 CAD. EBITDA per Share of Telo Genomics was 2024 -0.04 CAD. It decreases by 0.16% lower compared to the previous year.

The Telo Genomics EBITDA per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA per Share
Date
EBITDA per Share
Jan 1, 2018
-0.07 CAD
Jan 1, 2019
-0.04 CAD
Jan 1, 2020
-0.03 CAD
Jan 1, 2021
-0.02 CAD
Jan 1, 2022
-0.04 CAD
Jan 1, 2023
-0.04 CAD
Jan 1, 2024
-0.04 CAD
Jan 1, 2025
-0.04 CAD
The Telo Genomics EBITDA per Share history
YEAREBITDA per ShareYoY
-0.04CAD+0.16%
-0.04CAD-3.74%
-0.04CAD+10.08%
-0.04CAD+93.40%
-0.02CAD-36.14%
-0.03CAD-33.88%
-0.04CAD-35.77%
-0.07CAD-57.98%
-0.16CAD-1.26 M%
0.00CAD-100.05%
-0.03CAD+133.56%
-0.01CAD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Telo Genomics Stock analysis

What does Telo Genomics do? Telo Genomics Corp. develops and commercializes predictive technological products for personalized treatment plans, focusing on genomic instability-related diseases. Its lead product, TeloView SMM, is a high-complexity molecular assay for Smoldering Multiple Myeloma patients, using telomere-based analysis to identify high-risk cases needing early treatment and low-risk cases requiring no immediate intervention. The company operates through its wholly owned subsidiary Telo Genomics Holdings Corp., which develops diagnostic and prognostic products for diseases with genomic instability. Telo Genomics Corp. targets physicians and healthcare providers who treat patients with specific conditions requiring personalized therapeutic approaches. The firm's revenue model centers on the commercialization of TeloView SMM, which is available for clinical use. The assay provides critical information to physicians managing Smoldering Multiple Myeloma, enabling tailored treatment decisions. Telo Genomics Holdings Corp. focuses on developing additional diagnostic and prognostic products within the genomic instability disease space, aiming to expand its product portfolio for healthcare providers seeking advanced diagnostic tools. The company's primary customers are medical professionals and healthcare institutions specializing in oncology and hematology, particularly those treating myeloma patients. Telo Genomics Corp. differentiates itself through telomere-based analysis technology, which allows precise risk stratification for Smoldering Multiple Myeloma patients. This approach supports early intervention for high-risk patients while avoiding unnecessary treatments for low-risk cases. The company's product line is designed to address specific clinical needs within the oncology sector, targeting healthcare providers who require accurate diagnostic tools to optimize patient care pathways. The firm's focus on genomic instability diseases positions it within a niche market requiring specialized diagnostic solutions. Telo Genomics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Telo Genomics stock

EBITDA per Share of Telo Genomics is -0.04 CAD in 2025.

EBITDA per Share of Telo Genomics changed from -0.04 CAD to -0.04 CAD, representing a 0.16% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA per Share Telo Genomics since 2006 – with annual values, charts, and detailed analysis.

EBITDA per share divides EBITDA by shares outstanding, showing the operating cash earnings allocated to each share before depreciation and financing effects.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Telo Genomics

All Key Metrics — Telo Genomics